BDR Pharmaceutical today announces the launch of 4mg and 10 mg of Lenvatinib under the brand name BDFOIE for the treatment of differentiated thyroid cancer, advanced liver
Tag: BDR Pharma
BDR Pharma launches Nintenib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis in India
BDR Pharmaceutical today announces the launch of 100mg and 150 mg Nintedanib under the brand name Nintenib for the treatment of Idiopathic Pulmonary Fibrosis (IPF).